「智冉医疗」再获3亿元A+轮融资，2026计划启动规模化注册临床试验｜早起看早期

Group 1 - The core viewpoint of the article is that Zhiran Medical, a company specializing in invasive brain-machine interfaces, has successfully secured a 300 million yuan A+ round of financing, indicating strong investor confidence in its capabilities [3][4] - The funding will primarily be used to advance large-scale clinical trials and iterate on high-throughput flexible brain-machine interface products, accelerating the clinical application of invasive brain-machine interface technology [4] - The founder and CEO of Zhiran Medical, Song Qi, emphasizes the company's commitment to invasive brain-machine interfaces, highlighting the team's deep technical expertise and the potential for efficient human-machine information exchange [4][5] Group 2 - Zhiran Medical has developed a high-throughput "stretchable flexible electrode" that can dynamically follow the brain's movements, ensuring long-term stability within brain tissue and reducing mechanical damage compared to traditional linear electrodes [5][7] - The company has also made significant progress in the fields of neural chips, decoding algorithms, and electrode implantation robots, establishing a nearly 2000 square meter clinical-grade micro-nano processing workshop and GMP-standard assembly workshop for full-chain control of clinical-grade products [7] - By 2025, Zhiran Medical plans to complete clinical implants of its high-throughput invasive brain-machine interface products, with a large-scale registration clinical trial set to begin in 2026 [7][8] Group 3 - The invasive brain-machine interface technology is positioned as a key future industry in China's "14th Five-Year Plan," with various regions establishing special funds worth billions to support its development [8] - The National Healthcare Security Administration plans to include multiple services related to brain-machine interfaces as independent billing items, reflecting a strong commitment to supporting the industry's growth [8]